Etoricoxib

What it isHighly COX-2-selective NSAID that inhibits prostaglandin synthesis while largely sparing COX-1, reducing gastrointestinal mucosal toxicity.

Why this oneMarketed outside the U.S. for osteoarthritis, rheumatoid arthritis, gout, and acute pain with convenient once-daily dosing.

What limits itIt was rejected by the FDA over cardiovascular thrombotic and hypertension concerns and is not marketed in the U.S.; like all NSAIDs it raises cardiovascular and GI-bleeding risk.